Pathologie de l'endothélium, Biologie et pathologie du coeur et des vaisseaux. Esther: John Libbey Eurotext, pp.343-67, 2007. ,
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo, Circulation, vol.91, pp.1314-1323, 1995. ,
Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation, Hypertension, vol.48, pp.1088-94, 2006. ,
Characterization of a coronary vasoconstrictor produced by cultured endothelial cells, Am J Physiol, vol.248, pp.550-556, 1985. ,
A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, vol.332, pp.411-416, 1988. ,
Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color, Proc Natl Acad Sci, vol.93, pp.867-72, 1996. ,
Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons, Nature, vol.452, pp.759-63, 2008. ,
Interaction of endothelin-1 with cloned bovine ETA receptors: biochemical parameters and functional consequences, Biochemistry, vol.35, pp.14868-75, 1996. ,
Polar secretion of endothelin-1 by cultured endothelial cells, J Biol Chem, vol.267, pp.16066-16074, 1992. ,
Differential pharmacological profile of endothelin-1 and its precursor, big endothelin, J Cardiovasc Pharmacol, vol.17, issue.7, pp.362-367, 1991. ,
Why are circulating concentrations of endothelin-1 so low?, Cardiovasc Res, vol.28, pp.1613-1635, 1994. ,
Is plasma endothelin a marker of endothelial dysfunction, The endothelin system in cardiopulmonary diseases, pp.33-44, 2004. ,
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide, J Clin Invest, vol.85, pp.587-90, 1990. ,
Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells, J Biol Chem, vol.269, pp.11938-11982, 1994. ,
In vivo evidence of an endothelininduced vasopressor tone after inhibition of nitric oxide synthesis in rats, Circulation, vol.91, pp.771-776, 1995. ,
Pulmonary endothelinergic system in experimental congestive heart failure, Cardiovasc Res, vol.49, pp.330-339, 2001. ,
Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure, Circulation, vol.101, pp.2764-70, 2000. ,
Expression of endothelin-1 in the lungs of patients with pulmonary hypertension, N Engl J Med, vol.328, pp.1732-1741, 1993. ,
The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs, Am J Physiol Lung Cell Mol Physiol, vol.280, pp.258-63, 2001. ,
Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors, J Appl Physiol, vol.81, pp.1510-1515, 1996. ,
Human pulmonary circulation is an important site for both clearance and production of endothelin-1, Circulation, vol.94, pp.1578-84, 1996. ,
Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension, Am Heart J, vol.135, pp.614-634, 1998. ,
Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction, Circulation, vol.98, pp.1684-1691, 1998. ,
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade, Circulation, vol.100, pp.5-8, 1999. ,
Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes, J Clin Invest, vol.92, pp.398-403, 1993. ,
Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes, Circ Res, vol.69, pp.209-224, 1991. ,
Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice, Circulation, vol.109, pp.255-61, 2004. ,
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1, J Invest Dermatol, vol.116, pp.417-442, 2001. ,
Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro, Am J Respir Cell Mol Biol, vol.11, pp.439-484, 1994. ,
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice, Am J Respir Cell Mol Biol, vol.23, pp.19-26, 2000. ,
Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors, Br J Pharmacol, vol.115, pp.227-263, 1995. ,
Endothelin-1 induces interleukin-6 release via activation of the transcription factor NFkappaB in human vascular smooth muscle cells, Basic Res Cardiol, vol.95, pp.98-105, 2000. ,
Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1, Fundam Clin Pharmacol, vol.22, pp.649-55, 2008. ,
Mechanisms of ET-1-induced endothelial dysfunction, J Cardiovasc Pharmacol, vol.50, pp.621-629, 2007. ,
Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries, Hypertension, vol.19, pp.131-138, 1992. ,
receptor blockade unmasks a depressor response to endothelin antagonists in rats, Fundam Clin Pharmacol, vol.14, pp.101-107, 2000. ,
Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats, Hypertension, vol.27, pp.1153-1162, 1996. ,
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner, Hypertension, vol.57, pp.755-63, 2011. ,
Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure, J Cardiovasc Pharmacol, vol.43, pp.489-94, 2004. ,
Pharmacological characterization of bosentan, a new potent orally active nonpe-ptide endothelin receptor antagonist, J Pharmacol Exp Ther, vol.270, pp.228-263, 1994. ,
Ambrisentan, a nonpeptide endothelin receptor antagonist, Cardiovasc Drug Rev, vol.24, pp.63-76, 2006. ,
Evidence for endothelin involvement in the response to high salt . A m, J Physiol Renal phy si o l, vol.281, pp.144-50, 2001. ,
Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors, Am J Physiol Heart Circ Physiol, vol.283, pp.1555-61, 2002. ,
Short-term oral endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure, Circulation, vol.98, pp.2262-2270, 1998. ,
Receptorand non-receptor-mediated clearance of big endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade, J Hypertens, vol.18, pp.273-282, 2000. ,
Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure ET 003 Investigators, J Am Coll Cardiol, vol.35, pp.1745-52, 2000. ,
Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow, Circulation, vol.108, pp.1646-54, 2003. ,
Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension, Circulation, vol.105, pp.1034-1040, 2002. ,
Endothelin system-dependent cardiac remodeling in renovascular hypertension, Hypertension, vol.33, pp.816-838, 1999. ,
Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat, vol.102, pp.491-494, 2000. ,
Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensinconverting enzyme inhibition in rats with chronic heart failure, vol.106, pp.1159-64, 2002. ,
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling, Circulation, vol.96, pp.1976-82, 1997. ,
Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension, Circulation, vol.103, pp.314-322, 2001. ,
Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure, Cardiovasc Res, vol.39, pp.600-608, 1998. ,
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan), Circulation, vol.90, pp.2510-2518, 1994. ,
Inhibition of myocardial endothelin pathway improves long-term s u rv, vol.384, pp.353-358, 1996. ,
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure, Lancet, vol.346, pp.732-738, 1995. ,
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure, J Am Coll Cardiol, vol.42, pp.140-147, 2003. ,
Shortterm haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure, Lancet, vol.352, pp.201-203, 1998. ,
Clinical trials of endothelin antagonists in heart failure, E x p B i o l M e d, vol.231, pp.696-705, 2006. ,
Endothelin receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats, J Appl Physiol, vol.79, pp.2122-2153, 1995. ,
Effects of selective and unselective endothelin receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension, Scand J Clin Lab Invest, vol.68, pp.270-276, 2008. ,
Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats, Am J Physiol, vol.268, pp.828-863, 1995. ,
Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, vol.346, pp.896-903, 2002. ,
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial, Lancet, vol.371, pp.2093-100, 2008. ,
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study, Lancet, vol.358, pp.1119-1142, 2001. ,
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2, Circulation, vol.117, pp.3010-3019, 2008. ,
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension, J Am Coll Cardiol, vol.54, pp.1971-81, 2009. ,
Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension, Am J Cardiol, vol.108, pp.302-309, 2011. ,
Sitaxsentan therapy for pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.169, pp.441-448, 2004. ,
Survival with firstline bosentan in patients with primary pulmonary hypertension, Eur Respir J, vol.25, pp.244-253, 2005. ,
Effects of longterm bosentan in children with pulmonary arterial hypertension, J Am Coll Cardiol, vol.46, pp.697-704, 2005. ,
Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension, Circulation, vol.121, pp.20-25, 2010. ,
Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management, Eur Respir J, vol.19, pp.314-334, 2010. ,
Longterm effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension, vol.67, pp.1222-1230, 2008. ,
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, vol.50, pp.3985-93, 2004. ,
Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur Heart J, vol.30, pp.2493-537, 2009. ,
Macitentan), an orally active, potent dual endothelin receptor antagonist, J Med Chem, vol.55, pp.7849-61, 2012. ,
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist, J Pharmacol Exp Ther, vol.327, pp.736-781, 2008. ,
Optimization of tissuetargeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension, Am J Respir Crit Care Med, vol.183, p.6445, 2011. ,
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells, PLoS One, vol.7, p.47662, 2012. ,
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans, Xenobiotica, vol.42, pp.901-911, 2012. ,
Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist, AAPS J, vol.14, pp.68-78, 2012. ,
entry-intohumans study with a new endothelin receptor antagonist, Eur J Clin Pharmacol, vol.67, pp.977-84, 2011. ,
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects, J Clinical Pharmacol, 2013. ,
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions, Clin Pharmacol Ther, vol.69, pp.223-254, 2001. ,
Macitentan a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis, Curr Opin Investig Drugs, vol.11, pp.1066-73, 2010. ,
Macitentan and morbidity and mortality in pulmonary arterial hypertension, N Engl J Med, vol.369, pp.809-827, 2013. ,
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial, Eur Respir J, vol.42, pp.1622-1654, 2013. ,
Lack of clinically relevant pharmacokinetic interactions between the dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects, Am J Respir Crit Care Med, vol.185, 2012. ,
Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects, Am J Respir Crit Care Med, vol.185, p.950, 2012. ,
Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects, Clinical pharmacokinetics, vol.52, pp.685-92, 2013. ,
Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A, Kidney Int, vol.57, pp.224-255, 2000. ,